Botanix Pharmaceuticals Ltd (BOT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Botanix Pharmaceuticals Ltd (BOT) has a cash flow conversion efficiency ratio of -0.591x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-48.02 Million ≈ $-33.98 Million USD) by net assets (AU$81.30 Million ≈ $57.52 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BOT net asset quality index to measure how much of total assets are equity-financed.
Botanix Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (1991–2025)
This chart illustrates how Botanix Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Botanix Pharmaceuticals Ltd to evaluate the quality of earnings relative to operating cash generation.
Botanix Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Botanix Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bintai Kinden Corporation Bhd
KLSE:6998
|
0.007x |
|
Briacell Therapeutics Corp
NASDAQ:BCTX
|
-0.302x |
|
Derwent London PLC
LSE:DLN
|
0.047x |
|
CIFI Holdings (Group) Co. Ltd
F:6CI
|
0.064x |
|
Sapmer
PA:ALMER
|
0.004x |
|
Dominant Enterprise Bhd
KLSE:7169
|
0.008x |
|
Goldbank Mining Corp
V:GLB
|
0.005x |
|
Wiseway Group Ltd
AU:WWG
|
0.102x |
Annual Cash Flow Conversion Efficiency for Botanix Pharmaceuticals Ltd (1991–2025)
The table below shows the annual cash flow conversion efficiency of Botanix Pharmaceuticals Ltd from 1991 to 2025. For the full company profile with market capitalisation and key ratios, see BOT market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$81.30 Million ≈ $57.52 Million |
AU$-78.58 Million ≈ $-55.60 Million |
-0.967x | -1193.21% |
| 2024-06-30 | AU$108.73 Million ≈ $76.94 Million |
AU$-8.13 Million ≈ $-5.75 Million |
-0.075x | +85.79% |
| 2023-06-30 | AU$22.95 Million ≈ $16.24 Million |
AU$-12.07 Million ≈ $-8.54 Million |
-0.526x | +61.66% |
| 2022-06-30 | AU$8.15 Million ≈ $5.77 Million |
AU$-11.18 Million ≈ $-7.91 Million |
-1.372x | -861.49% |
| 2021-06-30 | AU$20.80 Million ≈ $14.72 Million |
AU$-2.97 Million ≈ $-2.10 Million |
-0.143x | +80.57% |
| 2020-06-30 | AU$23.64 Million ≈ $16.72 Million |
AU$-17.36 Million ≈ $-12.28 Million |
-0.734x | +96.56% |
| 2019-06-30 | AU$615.22K ≈ $435.30K |
AU$-13.14 Million ≈ $-9.30 Million |
-21.360x | -3410.32% |
| 2018-06-30 | AU$16.28 Million ≈ $11.52 Million |
AU$-9.91 Million ≈ $-7.01 Million |
-0.608x | +28.70% |
| 2017-06-30 | AU$5.44 Million ≈ $3.85 Million |
AU$-4.64 Million ≈ $-3.28 Million |
-0.853x | -40490.24% |
| 2016-06-30 | AU$3.18 Million ≈ $2.25 Million |
AU$-6.69K ≈ $-4.73K |
-0.002x | +99.79% |
| 2015-06-30 | AU$1.23 Million ≈ $869.58K |
AU$-1.20 Million ≈ $-851.81K |
-0.980x | -70.31% |
| 2014-06-30 | AU$2.24 Million ≈ $1.59 Million |
AU$-1.29 Million ≈ $-913.02K |
-0.575x | -238.34% |
| 2013-06-30 | AU$-2.50 Million ≈ $-1.77 Million |
AU$-1.04 Million ≈ $-735.77K |
0.416x | -13.19% |
| 2012-06-30 | AU$-2.33 Million ≈ $-1.65 Million |
AU$-1.12 Million ≈ $-790.81K |
0.479x | +54.21% |
| 2011-06-30 | AU$-2.23 Million ≈ $-1.58 Million |
AU$-692.97K ≈ $-490.32K |
0.311x | -35.20% |
| 2010-06-30 | AU$-1.80 Million ≈ $-1.27 Million |
AU$-861.12K ≈ $-609.30K |
0.479x | +125.99% |
| 2009-06-30 | AU$877.74K ≈ $621.06K |
AU$-1.62 Million ≈ $-1.15 Million |
-1.844x | +0.15% |
| 2008-06-30 | AU$1.29 Million ≈ $909.99K |
AU$-2.38 Million ≈ $-1.68 Million |
-1.847x | -94.45% |
| 2007-06-30 | AU$2.90 Million ≈ $2.05 Million |
AU$-2.75 Million ≈ $-1.95 Million |
-0.950x | +29.94% |
| 2006-06-30 | AU$2.22 Million ≈ $1.57 Million |
AU$-3.01 Million ≈ $-2.13 Million |
-1.356x | -64.76% |
| 2005-06-30 | AU$3.46 Million ≈ $2.45 Million |
AU$-2.84 Million ≈ $-2.01 Million |
-0.823x | -213.18% |
| 2004-06-30 | AU$2.24 Million ≈ $1.59 Million |
AU$-589.68K ≈ $-417.24K |
-0.263x | +9.32% |
| 2002-06-30 | AU$4.05 Million ≈ $2.86 Million |
AU$-1.17 Million ≈ $-829.68K |
-0.290x | -395.90% |
| 2001-06-30 | AU$5.69 Million ≈ $4.03 Million |
AU$-332.70K ≈ $-235.40K |
-0.058x | +80.44% |
| 2000-06-30 | AU$5.15 Million ≈ $3.64 Million |
AU$-1.54 Million ≈ $-1.09 Million |
-0.299x | +45.25% |
| 1999-06-30 | AU$8.08 Million ≈ $5.72 Million |
AU$-4.41 Million ≈ $-3.12 Million |
-0.546x | -218.85% |
| 1998-06-30 | AU$15.75 Million ≈ $11.15 Million |
AU$7.23 Million ≈ $5.12 Million |
0.459x | +547.35% |
| 1997-06-30 | AU$32.05 Million ≈ $22.67 Million |
AU$-3.29 Million ≈ $-2.33 Million |
-0.103x | -8556.45% |
| 1996-06-30 | AU$37.91 Million ≈ $26.83 Million |
AU$46.00K ≈ $32.55K |
0.001x | -99.25% |
| 1995-06-30 | AU$38.44 Million ≈ $27.20 Million |
AU$6.24 Million ≈ $4.42 Million |
0.162x | +68.58% |
| 1994-06-30 | AU$26.04 Million ≈ $18.43 Million |
AU$2.51 Million ≈ $1.78 Million |
0.096x | +25.35% |
| 1993-06-30 | AU$18.35 Million ≈ $12.98 Million |
AU$1.41 Million ≈ $997.66K |
0.077x | -39.42% |
| 1992-06-30 | AU$11.41 Million ≈ $8.07 Million |
AU$1.45 Million ≈ $1.02 Million |
0.127x | -15.46% |
| 1991-06-30 | AU$12.88 Million ≈ $9.11 Million |
AU$1.93 Million ≈ $1.37 Million |
0.150x | -- |
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment o… Read more